If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-15. Numbers and descriptions here follow the published literature rather than marketing material.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Naloxone, sold under the brand name Narcan among others, is an opioid antagonist, a medication used to reverse or reduce the effects of opioids. Naloxone is commonly used to restore breathing after an opioid overdose. Effects begin within two minutes when given intravenously, five minutes when injected into a muscle, and ten minutes as a nasal spray. Naloxone has also been said to have an onset of action of 3–7 minutes as an intranasal. Naloxone blocks the effects of opioids for 30 to 90 minutes. Administration to opioid-dependent individuals may cause symptoms of opioid withdrawal, including restlessness, agitation, nausea, vomiting, a fast heart rate, and sweating. To prevent this, small doses every few minutes can be given until the desired effect is reached. In those with previous heart disease or taking medications that negatively affect the heart, further heart problems have occurred. There is limited data on naloxone's safety during pregnancy. Naloxone is a non-selective and competitive opioid receptor antagonist. It reverses the depression of the central nervous system and respiratory system caused by opioids. Naloxone was patented in 1961 and approved for opioid overdose in the United States in 1971. It is on the World Health Organization's List of Essential Medicines. Naloxone is available as an over-the-counter medication.
== Side effects == Possible adverse effects include temporary bone pain, joint pains (arthralgias), dizziness, elevated blood pressure (hypertension) and elevated uric acid levels (hyperuricemia). There was also an increased risk of thrombosis (blood clots) in patients who have risk factors for thrombosis who are taking luspatercept.
Temperature If the relative humidity is kept constant, the higher the temperature, the higher the drying rate. Temperature influences the drying rate by increasing the moisture holding capacity of the air, as well as by accelerating the diffusion rate of moisture through the wood. The actual temperature in a drying kiln is the dry-bulb temperature (usually denoted by Tg), which is the temperature of a vapour-gas mixture determined by inserting a thermometer with a dry bulb. On the other hand, the wet-bulb temperature (TW) is defined as the temperature reached by a small amount of liquid evaporating in a large amount of an unsaturated air-vapour mixture. The temperature sensing element of this thermometer is kept moist with a porous fabric sleeve (cloth) usually put in a reservoir of clean water. A minimum air flow of 2 m/s is needed to prevent a zone of stagnant damp air formation around the sleeve. Since air passes over the wet sleeve, water is evaporated and cools the wet-bulb thermometer. The difference between the dry-bulb and wet-bulb temperatures, the wet-bulb depression, is used to determine the relative humidity from a standard hygrometric chart. A higher difference between the dry-bulb and wet-bulb temperatures indicates a lower relative humidity. For example, if the dry-bulb temperature is 100 °C and wet-bulb temperature 60 °C, then the relative humidity is read as 17% from a hygrometric chart.
== Biological function == In 1962, J.C. Watkins reported synthesizing NMDA, an isomer of the previously known N-Methyl-DL-aspartic-acid. NMDA is a water-soluble D-alpha-amino acid — an aspartic acid derivative with an N-methyl substituent and D-configuration — found across Chordates from lancelets to mammals. At homeostatic levels NMDA plays an essential role as a neurotransmitter and neuroendocrine regulator. At increased but sub–toxic levels NMDA becomes neuroprotective. In excessive amounts NMDA is an excitotoxin. Behavioral neuroscience research utilizes NMDA excitotoxicity to induce lesions in specific regions of an animal subject's brain or spinal cord to study behavioral changes. The mechanism of action for the NMDA receptor is a specific agonist binding to its NR2 subunits, and then a non-specific cation channel is opened, which can allow the passage of Ca2+ and Na+ into the cell and K+ out of the cell. Therefore, NMDA receptors will only open if glutamate is in the synapse and concurrently the postsynaptic membrane is already depolarized - acting as coincidence detectors at the neuronal level. The excitatory postsynaptic potential (EPSP) produced by activation of an NMDA receptor also increases the concentration of Ca2+ in the cell. The Ca2+ can in turn function as a second messenger in various signaling pathways. This process is modulated by a number of endogenous and exogenous compounds and plays a key role in a wide range of physiological (such as memory) and pathological processes (such as excitotoxicity).
On 9 July, Thom took Florey and Heatley to Washington, D.C., to meet Percy Wells, the acting assistant chief of the USDA Bureau of Agricultural and Industrial Chemistry and as such the head of the USDA's four laboratories. Wells sent an introductory telegram to Orville May, the director of the UDSA's Northern Regional Research Laboratory (NRRL) in Peoria, Illinois. They met with May on 14 July, and he arranged for them to meet Robert D. Coghill, the chief of the NRRL's fermentation division, who raised the possibility that fermentation in large vessels might be the key to large-scale production. On 17 August, Florey met with Alfred Newton Richards, the chairman of the Committee for Medical Research (CMR) of the Office of Scientific Research and Development (OSRD), who promised his support. On 8 October, Richards held a meeting with representatives of four major pharmaceutical companies: Squibb, Merck, Pfizer and Lederle. Vannevar Bush, the director of OSRD was present, as was Thom, who represented the NRRL. Richards told them that antitrust laws would be suspended, allowing them to share information about penicillin. This was not legalized until 7 December 1943, and it covered only penicillin and no other drug. OSRD arranged with the War Production Board (WPB) for them to have priority for equipment for laboratories and pilot plants.
Sources: en.wikipedia.org
== Management == There is no standard course of treatment to slow or stop the progression of the disease as of 2019. sIBM patients do not reliably respond to anti-inflammatory, immunosuppressant, or immunomodulatory medications. Most of disease management is supportive care. Prevention of falls is an important consideration. There is no consensus on exercise guidelines; however, physical therapy is recommended to teach the patient a home exercise program, to teach how to compensate during mobility-gait training with an assistive device, transfers and bed mobility. An exercise regimen preferentially minimizes a patient's risk of injury and corresponds to the patient's goals.
The role of NE in schizophrenia has not been fully understood, but has stimulated research into this topic. The only relationship that has been understood between researchers is that there is a positive correlation between increased NE levels in the brain and spinal fluid (CSF) and activity of schizophrenia. In one study, clonidine, a drug used to treat medical conditions such as ADHD and high blood pressure, was shown to produce a significant decrease in plasma level MHPG (3-methoxy-4-hydroxyphenylglycol), a metabolite of NE, in the normal control group, but not in the group of schizophrenic patients. This suggests that in schizophrenia, the alpha-2 adrenergic receptor, a presynaptic inhibitory receptor, may be less sensitive compared to normally functioning alpha-2 receptors and thus relate to elevated NE levels in the disorder. In addition to increased NE levels in the brain and CSF, increased levels of MHPG has also been associated with a diagnosis of schizophrenia. Impaired NE regulation in schizophrenia has been an area of interest for researchers and research on this topic is still ongoing.
== Early autosomal research == Before the discovery of mtDNA variation and Y-chromosomal variation in the 1980s and 1990s, respectively, it was not possible to distinguish male from female effects in population genetics. Instead, researchers had to rely on autosomal variation, starting with the first population genetic study using blood groups by Ludwik Hirszfeld in 1919. Later other genetic polymorphisms were used, for example polymorphisms of proteins of the blood plasma, polymorphisms of human lymphocyte antigens or polymorphisms of immunoglobulins. On this basis, correlations between languages and genetic variation occasionally were proposed, but sex-specific questions could not be addressed until the 1990s, when both mtDNA and Y-chromosomal variation in humans became available for study.
glucogenic amino acid Any amino acid that can be converted into glucose via gluconeogenesis, as opposed to the ketogenic amino acids, which can be converted into ketone bodies. In humans, 18 of the 20 amino acids are glucogenic; only leucine and lysine are not. Five amino acids (phenylalanine, isoleucine, threonine, tryptophan, and tyrosine) are both glucogenic and ketogenic.
=== Secret peace discussions, opposition to troop withdrawals === In June 1969, the former Defense Secretary Clark Clifford published an article in Foreign Affairs calling for the withdraw of 100,000 U.S. troops from Vietnam by the end of 1969 and all by the end of 1970. Influenced by Laird, Nixon announced the immediate withdraw of 25,000 U.S. troops from Vietnam, saying: "I would hope that we could beat Mr. Clifford's timetable". Kissinger was opposed to the withdrawal, which he predicted would mean the immediate collapse of South Vietnam. On 4 August 1969, Kissinger met secretly with Xuân Thủy at the Paris apartment of Jean Sainteny to discuss peace. Sainteny was a former French colonial official sympathetic to Vietnamese nationalism who had offered to serve as an honest broker. Kissinger had been hoping to see Tho rather than Thuy. Kissinger repeated the American offer of "mutual withdrawal" of U.S. and North Vietnamese forces from South Vietnam, which Thủy rejected, while Thủy demanded a new government in Saigon, which Kissinger rejected. Kissinger had a low opinion of North Vietnam, saying "I can't believe that a fourth-rate power like North Vietnam doesn't have a breaking point". Kissinger was opposed to the strategy of Vietnamization, expressing some doubt about the ability of the ARVN (Army of the Republic of Vietnam-i.e. the South Vietnamese Army) to hold the field, causing much tension with Defense Secretary Laird who was deeply committed to Vietnamization. In September 1969, Kissinger, in a memo, advised Nixon against "de-escalation", saying that keeping U.S.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.